Bioatla Stock News

SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of…

BioAtla, Inc. (NASDAQ:BCAB)s share price rose 6.5% during trading on Monday . The stock traded as high as $22.91 and last traded at $22.47. Approximately 2,165 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 231,130 shares. The stock had previously closed at $21.10. Separately, Zacks Investment Research []

BioAtla, Inc. (NASDAQ:BCAB)s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $21.28 and last traded at $21.34, with a volume of 7866 shares trading hands. The stock had previously closed at $23.41. Separately, Zacks Investment Research upgraded shares of BioAtla from a sell rating []

BioAtla, Inc. (NASDAQ:BCAB) insider Christian Vasquez sold 1,011 shares of the businesss stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $23.04, for a total transaction of $23,293.44. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Christian Vasquez also []

BioAtla, Inc. (NASDAQ:BCAB) CEO Jay M. Phd Short sold 15,435 shares of the stock in a transaction that occurred on Monday, November 29th. The shares were sold at an average price of $23.89, for a total transaction of $368,742.15. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. []

BioAtla, Inc. (NASDAQ:BCAB) President Scott Andrew Smith sold 628 shares of the firms stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $23.03, for a total transaction of $14,462.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this []

BioAtla, Inc. (NASDAQ:BCAB) CFO Richard A. Waldron sold 7,246 shares of the stock in a transaction on Wednesday, December 1st. The stock was sold at an average price of $23.03, for a total value of $166,875.38. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Shares of []

BioAtla, Inc. (NASDAQ:BCAB) President Scott Andrew Smith sold 430 shares of the businesss stock in a transaction that occurred on Monday, November 22nd. The shares were sold at an average price of $26.23, for a total value of $11,278.90. The transaction was disclosed in a filing with the SEC, which is available through this link. []

BioAtla, Inc. (NASDAQ:BCAB) CFO Richard A. Waldron sold 3,937 shares of the companys stock in a transaction that occurred on Wednesday, November 24th. The stock was sold at an average price of $24.87, for a total value of $97,913.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Credit Suisse AG purchased a new stake in shares of BioAtla, Inc. (NASDAQ:BCAB) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 5,668 shares of the companys stock, valued at approximately $240,000. A number of other hedge funds and other institutional investors have also modified []

Citadel Advisors LLC lifted its stake in BioAtla, Inc. (NASDAQ:BCAB) by 82.3% during the second quarter, HoldingsChannel.com reports. The firm owned 152,999 shares of the companys stock after purchasing an additional 69,080 shares during the quarter. Citadel Advisors LLCs holdings in BioAtla were worth $6,484,000 as of its most recent SEC filing. Other institutional investors []

Related Stocks: BIIB , ANAB , CTMX , RIGL , BCAB , DRNA , VRTX , CYTK , URGN , XENE , PODD , MRTX , OCUL , XENT , KURA , VERV ,

SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therap

SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu

SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeu